Pharmala Biotech Holdings (XCNQ:MDMA) Cash-to-Debt : No Debt ⁽¹⁾ (As of Feb. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pharmala Biotech Holdings's cash to debt ratio for the quarter that ended in Feb. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pharmala Biotech Holdings could pay off its debt using the cash in hand for the quarter that ended in Feb. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Pharmala Biotech Holdings's Cash-to-Debt or its related term are showing as below:

XCNQ:MDMA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16 Med: No Debt Max: No Debt
Current: 0.16

During the past 3 years, Pharmala Biotech Holdings's highest Cash to Debt Ratio was No Debt. The lowest was 0.16. And the median was No Debt.

XCNQ:MDMA's Cash-to-Debt is ranked worse than
92.87% of 1528 companies
in the Biotechnology industry
Industry Median: 6.315 vs XCNQ:MDMA: 0.16

Pharmala Biotech Holdings Cash-to-Debt Historical Data

The historical data trend for Pharmala Biotech Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pharmala Biotech Holdings Cash-to-Debt Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Cash-to-Debt

No Debt

0.77

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Cash-to-Debt	Get a 7-Day Free Trial							No Debt	No Debt	0.77	No Debt	No Debt

Competitive Comparison of Pharmala Biotech Holdings's Cash-to-Debt

For the Biotechnology subindustry, Pharmala Biotech Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Cash-to-Debt falls into.

Pharmala Biotech Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pharmala Biotech Holdings's Cash to Debt Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.195	/	(0.254	+	0)
	=	0.77

Pharmala Biotech Holdings's Cash to Debt Ratio for the quarter that ended in Feb. 2024 is calculated as:

Pharmala Biotech Holdings had no debt ⁽¹⁾.

Pharmala Biotech Holdings (XCNQ:MDMA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pharmala Biotech Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings (XCNQ:MDMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PMBHF:USA

Address

82 Richmond Street East, Toranto, ON, CAN, M5C 1P1

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.

Pharmala Biotech Holdings (XCNQ:MDMA) Headlines

No Headlines

Pharmala Biotech Holdings (XCNQ:MDMA) Cash-to-Debt : No Debt (1) (As of Feb. 2024)